1.
New theory addresses frozen Earth paradox
LONDON, Oct. 24 (UPI) -- The European Medicines Agency is calling for suspension of marketing for the anti-obesity drug Acomplia after reports of psychiatric risks.
The EMEA's Committee for Medicinal Products for Human Use concluded that the benefits of Acomplia no longer outweigh its risks, the agency said Thursday. The drug rimonabant, marketed by Sanofi-Aventis as Acomplia, was approved for sale in the European United in 2006.
The agency said recent studies suggest an approximate doubling of the risk of psychiatric disorders in obese or overweight patients taking Acomplia compared to those taking placebo.
"Prescribers should not issue any prescriptions for Acomplia and should review the treatment of patients currently taking the medicine," the EMEA said in a statement. "Patients who are currently taking Acomplia should consult their doctor or pharmacist at a convenient time to discuss their treatment. There is no need for patients to stop treatment with Acomplia immediately, but patients who wish to stop can do so at any time."
|
|
|
|
|
|
| Additional Science News Stories | |
WASHINGTON, May 31 (UPI) --
The U.S. House Thursday rejected a bill that would outlaw abortions based on gender, with abortion opponents promising to make the vote an election issue.
|
NEW YORK, May 31 (UPI) --
"Glee" stars Samuel Larsen, Cory Monteith and Naya Rivera are to serve as guest mentors on the U.S. talent competition show "The Glee Project," Oxygen said.
|
BALTIMORE, May 31 (UPI) --
U.S. astronomers are forecasting the Milky Way will have a violent collision with the neighboring Andromeda galaxy in about 4 billion years.
|
CLEVELAND, May 31 (UPI) --
Cleveland prosecutors have dropped their case against a man who was ticketed for littering when he dropped a dollar he was attempting to give a disabled person.
|
| Stories | Photos | People | Comments |
View Caption
